Skip to main content
. 2021 Feb 15;12(2):186. doi: 10.1038/s41419-021-03458-5

Fig. 3. Caspase 3, rather than caspase 9, contributes to cisplatin- or doxorubicin-induced pyroptosis in HK-2 cells.

Fig. 3

A, E Representative light microscopy images of HK-2 cells treated with cisplatin (20 μM) or doxorubicin (4 μg/ml) in the presence or absence of CASP 3 or CASP 9 siRNA. A red arrow indicates bubbles emerging from the plasma membrane. Scale bar, 50 μm. Cytotoxicity and cell viability were determined using LDH assay (B, F) and CCK-8 detection (C, G) for HK-2 cells treated with cisplatin (20 μM) or doxorubicin (4 μg/ml) in the presence or absence of CASP 3 or CASP 9 siRNA. D, H Western blot analysis of cleavage of GSDME in cisplatin- (20 μM) or doxorubicin- (4 μg/ml) treated HK-2 cells in the presence or absence of CASP 3 or CASP 9 siRNA. All data are presented as mean ± SD from three independent experiments (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 using one-way ANOVA followed by the Tukey’s method.